

# CUMULATIVE INDEX 1996

## Volume 19

---

March	MOOD DISORDERS, pages 1-178
June	TREATMENT-RESISTANT DEPRESSION, pages 179-412
September	CONSULTATION-LIAISON PSYCHIATRY, pages 413-637
December	EATING DISORDERS, pages 638-882

---

*Note:* Page numbers of issue and article titles are in **boldface** type.

- Abstinence, in Overeaters Anonymous versus Alcoholics Anonymous, 831, 837
- Abuse, of psychostimulants, 540-541
- Acanthocytosis, in anorexia nervosa, 664
- Acetazolamide, in refractory depression, 339
- Addiction, to psychostimulants, 540-541
- Adjustment, of pediatric cancer survivors, 482-483
- Adolescent, response to serious illness, 487
- Advocates, patient, for eating-disorder treatment, under managed care, 801-802
- Affective disorders..See also *Bipolar disorder*.  
 anorexia nervosa in, 847  
 bulimia nervosa and, 853  
 eating disorders and, 647  
 five-factor model of, 116-118  
 Iowa 500 study of, 89-90  
 long-term naturalistic studies of (Zurich), 89  
 neuroimaging studies of, in adults, 261  
 in children, 262-263  
 treatment-resistant, clozapine for, 242  
 versus mood disorders, DSM-III and, 78-79
- Affectivity, mood state and trait dimensions and, 114  
 positive and negative, state versus trait in, 18-19
- Age, psychiatric sequelae of serious childhood illness and, 486-487
- Aggression, eating disorder expression of, feminist and psychoanalytical perspectives on, 823
- Alcoholism, treatment-resistant depression in, 319
- Alprazolam, in premenstrual dysphoric disorder, 363-364  
 response to, in double-blind studies, 189
- Alternative Criteria B for Dysthymic Disorder, DSM-IV appendix, 8-9, 42-43, 48, 112-113
- Alternative therapies, in chronic fatigue syndrome, 567
- Amenorrhea, in anorexia nervosa, 644-645, 672  
 persistent, 675-676  
 in athletes, 648-649
- Amitriptyline, for anorexia nervosa, 747
- Amphetamine, chemistry and pharmacology of, 516-518  
 drug interactions with, 537  
 for depressed medically ill patient, usage history, 520-521  
 history and evolution of use, 515
- Amylase, in eating disorders, 666
- Anemia, in anorexia nervosa, 664
- Anger, psychotherapy and, 301
- Anorexia nervosa, amenorrhea in, persistent, 675-676  
 as coping strategy, 715  
 assessment of, nutrition in, 702-703  
 biologic models of, 746  
 cardiovascular findings in, 662  
 cognitive-behavioral therapy for, 715-737  
 aims of, 716-717  
 assessment in, 719-725  
 assumptions in, 715-716  
 cognitive restructuring in, 730-731

Anorexia nervosa (*Continued*)

- collaboration and motivation in, 717-719
- coping strategies and contingencies in, 728, 730
- cost-benefit analysis in, 721, 723-725
- formulations in, food phobia, 721, 725
- interpersonal deficits in, 725
- interpersonal problems in, 731-732
- monitoring food intake and context in, 720-722, 735-736
- problem-solving in, 727-729, 736-737
- relapse-prevention in, 733-734
- review of functioning in, 719-720
- stages in, first, 716-731
- second, 731-734
- treatment in, 725-731
- weight restoration in, 725-727
- comorbidity studies of, 846-849
  - affective disorders in, 847
  - anxiety disorders in, 847-848
  - personality disorders in, 848-849
  - substance abuse in, 848
- complications of, pulmonary, 662
- electrocardiographic abnormalities in, 662
- electroconvulsive therapy for, 749-750
- endocrine aspects of, 670-673
- gastrointestinal findings in, 663
- hematology in, 663-664
- historical perspective on, 657-658
- incidence of, by case register studies
  - and hospital records, 682-688
  - case detection and, 681, 684
  - male:female ratio of, 688
- nutritional care in, dietary calcium in, 705-706
  - enteral or parenteral support in, 704
  - goals and strategies of, 704-705
  - hospital-based regimen, 703-706
  - patient education in, 705
  - zinc supplementation in, 705-706
- osteopenia and osteoporosis in, 673-674
- osteopenia in, 673-674
- outcome studies of, 844-846
  - mortality in, 844-845
  - predictors of outcome, 846
  - recovery in, process of, 846
  - rates of, 844
  - relapse and chronicity in, 845-846
- pharmacotherapy for, 745-750
  - antidepressants in, 746-747
  - clonidine in, 749
  - cypioheptadine in, 748
  - lithium in, 749
  - medical considerations in, 749-750
  - metoclopramide in, 749
  - neuroleptics in, 748-749
  - side effects of, 749-750
  - psychotherapy for, 746
  - treatment of, managed care limitations
    - on, medical sequelae of, 797
    - revolving door phenomenon with, 797
  - weight loss in, 646
  - with coexistent diabetes mellitus, 676
- Antiarhythmics, in chronic pain, 597-598
- Anticonvulsants, in chronic pain, 597
  - in treatment-resistant depression, 392-393
  - in bipolar disorder, 220-221
  - with selective serotonin reuptake inhibitors, 278-279
- Antidepressant(s). See also *Pharmacotherapy; specific drug or class, e.g. Fluoxetine; Tricyclic antidepressants (TCAs).*
  - dosage adequacy of, treatment-resistant depression and, 238-239
  - high-dose, 380, 388-392
  - in binge-eating disorder, 766-767
  - in bipolar disorder, 218-220, 223-224
  - in bulimia nervosa, 741-743
    - inadequate response to, 742-743
  - medical considerations with, 744-745
  - side effects of, 744-745
  - in chronic pain, 596-597
  - in combination therapy
    - anxiolytics and, 232
    - bupropion plus SSRI, 392
    - lithium and, 232
    - moclobemide plus SSRI, 392
    - tricyclic antidepressants plus monoamine oxidase inhibitors, 377-378, 392
    - tricyclic antidepressants plus selective serotonin reuptake inhibitors, 381-382, 391-392
  - in depression with personality disorder, 296-297
  - in double depression, 122-124
  - in elderly patients, 274-277
  - in fibromyalgia, 353-355
  - in heart transplantation patients, 624
  - in medical illness with depression, 331-339
  - in psychotic depression, treatment-resistant, 237, 239, 244-245
  - in rheumatoid arthritis, 580
  - new, bupropion, 509-510
    - clonazepam and psychotropic drug interactions and, 503
    - cytochrome P<sub>450</sub> enzymes and psychopharmacology and, 496-503
    - fluoxetine, 504
    - flvoxamine, 495-496, 504, 506-507
    - nefazodone, 507-509
    - selective serotonin reuptake inhibitors, 495-496
    - use in medically ill patient, 495-514

- venlafaxine, 506-507
- nonresponders to, dosage and plasma concentrations and, 373-374
  - duration of treatment and, 372-373
  - high-dose therapy for, 380
- response to, 127-129
  - noncompliance and, 271, 294
  - partial versus nonresponse, 181-182
    - predictors of, 184-186
  - personality and, 292-294
  - predictors of, 293
  - rates in double-blind studies, 187-193
- Antigluco corticoids, in treatment-resistant depression, 394-395
  - psychotic-type, 245-246
- Antihistamines, delirium and, 439
- Anxiety, as sudden cardiac death risk, 615-616
  - in chronic fatigue syndrome, 553-554
  - in chronic pain patient, 593
  - in depression, of bipolar disorder, 232
    - treatment response in, 185
  - in heart disease patients, 622-623
  - psychotherapy and, 300
- Anxiety disorders, anorexia nervosa and, 746, 847-848
  - bulimia nervosa and, 740, 746, 853-854
  - eating disorders and, 647
- Appetite suppressants, in binge-eating disorder, 767
  - long-term therapy with, 767-768
- Appropriateness of treatment, in managed care, 797
- Asian cultures, anorexia nervosa in, 696
- Athletes, amenorrhea in, 848-849
  - eating disorders in, 648-649
- Atlantic Province of Canada (Stirling County) Study, of depression and anxiety, 90-91
- Attitude, in bulimia nervosa, of client and nutritionist, 710
- Attributions, chronic fatigue syndrome and, 560
- Atypical facial pain, antidepressants in, 361
- Ballet students, eating disorders and, 695-696
- Beck Depression Inventory, in binge-eating disorder, 765
- Behavior, change of current, 162
- Beliefs, chronic pain and, 599-600
  - illness, chronic fatigue syndrome and, 567
  - loss of, in women with eating disorders, 781-782
- Benzodiazepines, in atypical facial pain, 361
- in chronic pain, 598
- refractory depression and, 316
- Binge eating, definitions of, 641, 643
  - gastrointestinal consequences of, 666-668
- Binge episode, definition of, 706
- Binge-eating disorder, assessment and treatment of, 761-772
  - assessment of, associated features in, 763-764
    - eating history in, 764-765
    - obesity in, 764
    - psychological dimension in, 765-766
    - treatment history in, 766
  - criteria for, 761-763
    - DSM-IV, 761, 763
  - treatment of, combination cognitive-behavior therapy-medication for, 768
    - psychopharmacotherapy for, 766-768
    - psychotherapy for, 768-769
  - typical patient with, 761-762
- Biopsychosocial model, pharmaco/psychotherapy and, 152
- Bipolar disorder, characteristics of, 216-217
  - chronic, in DSM-IV, 38-39
  - treatment-resistant depression in, 215-236
    - acute episodes of, 217
    - assessment of, 226
    - chronic, 217
    - cycle frequency in, 217-218
    - diagnosis of, 227-228
    - mood charts in, 226, 228
    - nonpharmacologic treatment of, 222
    - pharmacotherapy for, 218-224, 229, 232
    - treatment selection, staging, algorithms in, 223-226, 231
    - treatment strategies in, 223-224
      - multiphase, 224-230
      - phase-specific, 230-231
    - variants of, diagnosis of, 372
- Bipolar/cyclothymic disorder, 33-34
  - chronic depression versus, 34-35
- Body, ownership of, eating disorders and, feminist and psychoanalytic perspectives on, 816-818
- Body image disturbances, in eating disorders, 644
  - posttraumatic, in women with eating disorders, 779
- Bone marrow suppression, in bulimia nervosa, 663
- Borderline personality disorder, posttraumatic, in women with eating disorders, 780
  - with bulimia nervosa, 740-741
  - with treatment-resistant depression, in women, 293-294
  - psychotherapy for, 301-302

- Bradycardia, in anorexia nervosa, 660, 662
- Brain imaging, in chronic fatigue syndrome, 559
- Brief psychotherapy, in chronic fatigue syndrome, 566-567
- in depression, 622
- Bromocriptine, in treatment-resistant depression, 339, 396
- Bulimia nervosa, assessment in, nutritional, 706-707
- cognitive-behavioral approach to, 707-708
- comorbidity studies of, 852-855
- affective disorders in, 853
- anorexia nervosa in, 855
- anxiety disorders in, 853-854
- impulse-related disorders in, 855
- personality disorders in, 854
- substance abuse in, 854
- complications of, pulmonary, 662
- historical perspective on, 658
- incidence of, by case register studies and hospital records, 685-688
- nutrition intervention in, 707-710
- dietary counseling in, 708
- goals and principles of, 707
- osteopenia/osteoporosis in, 673
- outcome studies of, 849-855
- predictors of outcome in, 852
- recovery in, definition of, 849-850
- duration of follow-up and, 850
- process of, 852
- sample type in, 850-851
- relapse and chronicity of, 851-852
- outpatient management of, 707
- pharmacotherapy for, 740-745
- antidepressants in, 741-743
- comorbid psychiatric disorders and, 740-741
- maintenance, 743-744
- phenytoin in, 743
- psychotropic medications in, 743
- side effects and medical considerations with, 744-745
- Bulimic Cognitive Distortion Scale, 646
- Bulimorexia, 659
- Bupropion, in chronic fatigue syndrome with depression, 355
- in geriatric patients, 276-277
- in heart disease patient, 621
- in medically ill patient, 509-510
- in psychotic depression, 244-245
- response to, in double-blind studies, 191
- side effects of, 510
- with selective serotonin reuptake inhibitors, 392
- Buspirone, in augmentation strategies, 390-391
- in delirium, 442
- in premenstrual dysphoric disorder, 364
- Caffeine, refractory depression and, 317
- Calcium, dietary, in anorexia nervosa, 705
- Calcium-channel blockers, in chronic headache syndromes, 598
- Cancer, adult survivors of childhood, psychiatric sequelae in, 482-483
- Cancer patients, psychostimulants in, 338, 525-527
- Capitation, and managed care, for eating disorders, 802
- Carbamazepine, in neuropathic pain, 597
- in treatment-resistant depression, 393
- versus neuroleptics, in psychotic depression, 243
- Cardiovascular accident, depression following, psychostimulants for, 527-528
- Cardiovascular disease(s), congestive heart failure, confounding mental and physical symptoms in, 618
- coronary artery disease, anxiety and, 615-616
- depression and, 616-617
- Type A behavior and hostility and, 614-617
- denial in, 619
- new treatments and associated problems in, defibrillators, 624-625
- heart transplantation, 624
- left ventricular assist devices, 625-626
- patient issues in, 617-619
- psychiatric aspects of, 613-629
- anxiety, 622-623
- delirium, 623-624
- depression, 619-622
- patient problems, 617-624
- relationship problems in, 619
- with depression, antidepressants in, 333-335
- Cardiovascular system, abnormalities in, chronic fatigue syndrome and, 558
- adverse effects in, from psychostimulant drugs, 539-540
- Case, criteria for, 681, 684
- Case management, in managed care, 798
- in managed care company, provider alliance with, 801
- CBT. See *Cognitive-behavioral therapy (CBT)*.
- CDS. See *Collaborative Depression Study (CDS)*.
- Central nervous system, adverse effects in, from psychostimulant drugs, 539
- Characterologic-spectrum disorder, depression in, 106-107
- Child abuse, posttraumatic sequelae in women, alterations in systems of meaning, 781-782
- bodily shame and body image disturbance, 779
- dissociative symptoms and syndromes, 777-778

- disturbances in affect regulation, 775-776
  - biologic aspects of, 776
  - impulse-control disorders, 777
  - personality pathology, 779-781
  - self-mutilation, 776-777
  - somatization, 778-779
  - treatment of, family interventions, 784
    - giving back in, 785
    - group therapy, 783-784
    - individual psychotherapy in, 782-783
    - pharmacotherapy for, 784
  - sexual, eating disorders following, 773-774
- Child(ren), as extension of mother, 818
- dysthymic disorder in, symptomatology of, 45
- Child(ren) and adolescents, affective disorders in, neuroimaging studies of, 262-263
  - treatment-resistant depression in, definition of, 253
    - family studies of, 257-259
    - pharmacotherapy studies of, 254-256
    - psychosocial impairments in, 259-260
    - psychotherapy studies of, 256
- Chlorpromazine, in delirium, 441
- Cholinergic system, in delirium, 437-438
- Chronic depression. See also *Unipolar depression*.
  - and depressive personality, as disorder, 110
    - classification of, 109-110
    - dimensional models of affective structure and, 113-118
    - empirical relationship between, 111-113
  - combination treatment of, 155
    - clinical and empirical reasons for, 155
    - in double depression, 156
    - provider of, 167-168
    - rationale for, 168
    - regular meetings and communication in, 168-169
  - strategies in, determination of, 166-167
    - matching or prescriptive, 166
    - sequential model, 165
  - differential diagnosis of, associated medication condition in, 32
  - in DSM-IV, 32-39
    - major depressive disorder versus dysthymic disorder and, 35-36
    - versus bipolar/cyclothymic disorder, 34-35
    - versus personality disorder, 35
    - versus psychosis, 34
    - versus substance-induced mood disorder, 33
  - episodes of, treatment-resistant, 160
  - in DSM-III, classification of, 29-30
  - in DSM-IV, case examples of, 37-38
  - differential diagnosis of, 32-39
    - dysthymic disorder versus, 30-31
    - major depressive disorder versus, 30-31
  - nosology of, 30-31
    - subtypes of, 37
  - individual psychotherapy for, efficacy studies of, 161
    - recommendations for, 161-162
  - management of, 183-184, 201-213
  - pharmacotherapy for
    - in chronic depression, 127-129
    - in double depression, 122-124
    - in dysthymia, 124-127
    - long-term maintenance, 128-129
    - predictors of response to, 127-128
    - recommendations for, 129-130
    - studies of, 121-132
  - types and definitions of, 122
- Chronic depressive disorders, 29-39, 55-71, 121-132
  - conceptualization of, 104-109
  - differential diagnosis of, 13-14, 55-71
    - clinical course features and, 59
    - clinicians versus researchers and, 59-63
    - diagnostic specificity in, 56-59
    - DSM-II and, 56
    - DSM-III and, 56-57
    - DSM-III-R and, 58-59
    - DSM-IV Mood Disorders Field Trial and, 63-64
    - facilitation of, 63-68
    - in unipolar depression, 59-67
    - lifetime course profile in, 67-68
    - structured interview in, 65
    - structured retrospective recall in, 65-67
- Chronic fatigue syndrome, 549-573
  - antidepressants in, 355
  - assessment in, 563-564
    - biopsychosocial, 565
    - exclusion of organic disease in, 563
    - identification of psychiatric syndromes in, 563-564
    - patient characteristics in, 564
  - case definition of, 551-555
    - issues for, 552-555
  - case description in, 564-565
  - diagnosis and formulation in, 564
  - exercise therapy for, 566
  - fatigue and, as illness, 550
    - as symptom, 549-550
  - future directions in, 568
  - heterogeneous versus homogeneous, 555
  - management of, 563-568
    - potential problems in, 567

Chronic fatigue syndrome (*Continued*)

- multidimensional classification of, 555-556
  - nature and cause of, 549-562
    - biopsychosocial conceptualization of, 561-562
    - hypothetical model of, 562
  - overlaps in, with medically unexplained syndromes, 553
    - with psychiatric syndromes, 553-555
  - pharmacotherapy for, 566
  - poor prognosis patients and, 568
  - problem of medically unexplained illness and, 550-551
  - psychotherapy for, 566-567
  - research in, for objective evidence of impairment, 556-557
    - for psychopathology, 559-561
    - pathophysiology of, 557-559
  - service utilization in, 568
  - treatment of, 565-568
  - utility as diagnosis, 562
- Chronic mood disorders, 1-28, 103-120, 151-171
- and depressive personality, 103-120
  - chronic depression and, 109-118
  - conceptualizations of, 104-109
  - discussion of, 118-119
  - distinction between, 103-104
  - pharmac/psychotherapy for, 22-24, 151-171. See also *Pharmac/psychotherapy*.
- Chronic pain, antiarrhythmics for, 597-598
- anticonvulsants for, 597
  - antidepressants for, 596-597
  - anxiety and, 593
  - beliefs and, 599-600
  - benzodiazepines for, 598
  - cognitive-behavioral therapy for, 599
  - depression and, 592-593
  - opioids for, 595-596
  - pain disorder definition and, 590-591
  - self-efficacy and, 600
  - somatization and, 591-592
  - substance use and, 594
  - treatment of, by consultation-liaison psychiatrists, 594-604
  - multidisciplinary pain center in, 602-604
  - multidisciplinary versus interdisciplinary, 603
  - patient classifications and, 601-602
  - pharmacologic, 595-598
  - psychological, 599-602
- Chronic Pain Self-Efficacy Scale, 600
- Chronicity, of affective disorders, 89-90
- of major depression, measures of, 87-88
- Cingulotomy, in treatment-resistant depression, 399
- Clomipramine, in anorexia nervosa, 747

- Clonazepam, psychotropic drug
- interactions with, 503
- Clonidine, in anorexia nervosa, 749
- Clozapine, in psychotic depression, treatment-resistant, 240-242
- Cocaine abuse, treatment-resistant depression in, 319-320
- Cognitive distortions, in anorexia nervosa, diet and, 702
- in eating disorders, 641, 645-646
- Cognitive function, chronic fatigue syndrome and, 556
- Cognitive impairment, in general medical sector, length of stay and, 469
- Cognitive restructuring, in anorexia nervosa, 730-731
- Cognitive-behavioral therapy (CBT), antidepressant response and, 292-293, 304
- description of, 136-137
  - in anorexia nervosa, 715-737
  - in chronic fatigue syndrome, 567
  - in chronic mood disorders, 21
  - in dysthymic disorder, 136-139
  - in eating disorders, nutrition and, 707-708
  - in treatment-resistant depression, 398
  - outcome studies of, in double depression, 139
  - in dysthymic disorder, 137-138
  - response to, 137, 139
- Cognitive-behavioral therapy-medication combination, in bulimia nervosa, 755-760
- literature review of, 756-757
  - models for, 758-759
  - patient selection for, 757-768
  - treatment sequencing in, 758
- Collaboration, of therapist and anorexia nervosa patient, 717-719
- Collaborative Depression Study (CDS), 92-100
- common themes and findings in, 100
  - comparators in, 93-94
  - design of, 93
  - historical review of, 93-94
  - Longitudinal Interval Follow-up Evaluation interview in, 92-93
  - major depression at intake, functional outcomes in, 96-98
  - 10-year course of, 95-96
  - nonclinically ascertained group in, 93-94
  - predictors of course in, 98-99
  - recovery and recurrence in, 94
  - subjects in, 92
- Comorbidity studies, of anorexia nervosa, 846-849
- of bulimia nervosa, 852-855
- Competency determination, in terminally ill patient, legal standards for, 420-421

- psychiatrist role in, 420-422
- Complete blood count, in eating disorders, 663-664
- Compliance, with rheumatoid arthritis treatment, 581
- Confusion, in systemic lupus erythematosus, 582, 584
- Confusion Assessment Method (CAM), in delirium assessment, 435
- Constipation, during refeeding, 669
- Consultation-liaison, intervention models, for general hospital, 471
- Consultation-liaison psychiatry in managed care, 449-466. See also *Managed care*.
- consultation-liaison psychiatry in, history of, 450
- models of, 451
- recommendations for, 462-464
- training in, 450-451
- managed care, ethical issues and legal liability in, 458-462
- goals and organization of, 452-454
- mechanisms of, 454-457
- Contracting, between managed care companies and providers, 800
- Control, through eating disorders, for body ownership, 816-818
- Coping, definition of, 600
- with chronic fatigue syndrome patient, 560-561
- with chronic pain, 600-601
- with psychiatric sequelae of serious childhood illness and, 487-488
- with rheumatoid arthritis, 578
- Coping strategies, anorexia nervosa as, 715
- in anorexia nervosa treatment, 727-728
- Coronary artery disease, psychiatric and psychological factors in, anxiety, 615-616
- depression, 616-617
- Type A behavior and hostility in, 614
- Cortex, in delirium, 436
- Corticosteroids, for systemic lupus erythematosus, 584-585
- Cortisol, excess, in eating disorders, 672
- Cost-benefit analysis, of anorectic behaviors, 721, 723-725
- Course, descriptors of, for dysthymia and recurrent major depression, 63-64
- longitudinal, modifiers of, 81-82
- of major depression, population-based studies of, 90-92
- predictors of, 98-99
- 10-year, 85-86
- profile of lifetime, in differential diagnosis of double depression, 67-68
- Criterion variance, unreliability and, 77
- Culture, eating disorders and, feminist and psychoanalytic perspectives on, 814-815
- Cyclophosphamide, in systemic lupus erythematosus, 585
- Cyproheptadine, in anorexia nervosa, 747-748
- Cytochrome P<sub>450</sub> enzyme(s), CyP<sub>450</sub>IID6 isoenzyme, 496-500
- CyP<sub>450</sub>IIIA3/4, 500-501
- psychopharmacology and, drug biotransformation reactions, 496-497
- in poor metabolizers, 498-499
- selective serotonin reuptake inhibitor inhibition in, 499-500
- tricyclic antidepressants and, 499-500
- Cytochrome P<sub>450</sub>IID6 isoenzyme, cardiac drug-selective serotonin reuptake inhibitor interactions, 621
- Cytokines, delirium and, 439
- Damocles' syndrome, in childhood cancer survivors and families, 482-483
- DAMP. See *Dextroamphetamine (DAMP)*.
- Defibrillators, psychiatric problems associated with, 624-625
- Delirium, advances in diagnosis, pathophysiology, treatment, 429-448
- after cardiac surgery, 623
- drug interactions and, 623-624
- assessment of, 434-435
- diagnostic criteria for, general medical condition and, 432
- in DSM, DSM-II, DSM-III, DSM-III-R, DSM-IV, 431-433
- features of, 429
- hallucinations in, 433-434
- in children and adolescents, 431
- in elderly, 430-431
- in general medical inpatient sector, length of stay and, 469
- in systemic lupus erythematosus, 583-584
- neuropathophysiology of, 436-437
- neurotransmission in, 437-438
- phenomenology of, 433-434
- risk factors for, hypoalbuminemia, 430
- in elderly, 431
- thiamine deficiency, 430
- treatment of, environmental manipulation in, 439-440
- pharmacologic, 440-442
- Delirium Rating Scale (DRS), 434-435
- Dementia, in systemic lupus erythematosus, 583-584
- Denial, of cardiac disease, 619
- Depression. See also *Major depressive disorder (MDD)*.
- as coronary artery disease risk, 616-617
- atypical, psychopharmacologic treatment of, 339-340



Depression (*Continued*)

- bipolar, 38-39
- brief, recurrent, 9-10
- bulimia nervosa and, 853
- chronic, 29-39, 55-71, 121-132. See also *Chronic depression*.
- Collaborative Depression Study of, 92-100. See also *Collaborative Depression Study (CDS)*.
- competency determination in, 421
- double. See *Double depression*.
- historical perspective on, 104-105
- in adolescent survivors of pediatric cancer, 484
- in anorexia nervosa, 746
- in bulimia nervosa, 740, 746
- in children and adolescents. See also *Child(ren) and adolescents, treatment-resistant depression in*.
- in chronic fatigue syndrome, 553
- in chronic pain patient, 592-593
- in general medical sector, in patient, length of stay and, 469
- in heart disease patients, 619-622
  - brief psychotherapy for, 622
  - bupropion and, 621
  - trazodone and, 621-622
- in patient heart disease patients, selective serotonin reuptake inhibitors for, 620-621
- in primary outpatient care, cognitive-behavioral intervention for, 476
  - impact of, 472
  - outcome studies of, 472-474
- in rheumatoid arthritis, 579
- in systemic lupus erythematosus, 582, 584
- in terminally ill patient, 422-423
  - assisted suicide request and, 422-423
- major, 41-53, 88-102. See also *Major depression; Major depressive disorder (MDD)*.
- minor episode of, 9-10
- poststroke, 527-528
- psychopathologic factors in, 559-561
- psychotic, 229-230
- research criteria for, 92-93, 109
- steroid-induced, in transplant patients, 336-337
- treatment outcome in, primary care physician versus mental health professional, 473-474
- treatment-resistant. See *Treatment-resistant depression*.
- tricyclic antidepressants for, in patient with heart disease, 619-620
- unipolar, 14, 60
- Depression Time Line, in differential diagnosis, 65-67
- Depressive neurosis, DSM-II, 109
- Depressive personality disorder, 103-120.
  - See also *Chronic depression, and depressive personality*.
  - DSM-IV criteria for, 18, 110
  - historical perspective on, 17-18
- Desipramine, effect on social impairment, 127
  - in binge-eating disorder, 766-767
  - in chronic depression, 130
  - in double depression, 20
  - in dysthymia, 126
  - versus placebo, 124-125
  - long-term therapy with, response to, 128-129
  - with cognitive-behavioral therapy, in bulimia nervosa, 756-757
- Developmental arrest, adult, feminist and psychoanalytical perspectives on, 821-822
- Dexamethasone, in treatment-resistant depression, 395
- Dextroamphetamine (DAMP), chemistry and pharmacology of, 518-519
  - dosing of, 536-537
  - following head injury, 533-534
  - in cancer patients, 526-527
  - in combination therapy, with monoamine oxidase inhibitors, 340
  - in HIV-positive and AIDS patients, 530-532
  - in medically ill, depressed patients, 338, 340
  - in medical/surgical patients, 523-524
  - in multisystem disease patients, 522-523
  - in rehabilitation patients, 521-522
  - narcotic analgesia synergy with, 535
  - poststroke, 528-529
- Diabetes mellitus, with depression, 332-333
- Diagnostic and Statistical Manual-IV (DSM-IV) Mood Disorders Field Trial, assessments in, 3-4
  - design of, 2-3
  - interviewers in, training of, 4
  - interviewing in, 4-5
  - issues addressed in, 1-2
  - results of, 5-10, 24-25
    - brief depression, minor and recurrent and, 9-10
    - course modifiers for major depressive disorder, 5-6
    - dysthymic criteria, 79
  - subjects in, 3
  - summary of, 1-28
- Diagnostic Interview for Depressive Personality (DID-P), in DSM-IV Mood Disorders Field Trial, 4
- DID-P (Diagnostic Interview for Depressive Personality), in DSM-IV Mood Disorders Field Trial, 4



- Dietary counseling, in bulimia nervosa, 708
- Dieting behavior, and Western acculturation, 696-697
- epidemiology of, 693-695
- Disability, chronic fatigue syndrome patient and, 567-568
- Dissociative syndromes, in women, following child abuse, 777-778
- Dopaminergic agents, in treatment-resistant depression, 396
- Dopaminergic system, in delirium, 437-438
- Double depression, course of, features of, 60-61
- definition of, 122
- DSM-III-R, 57-58
- differential diagnosis of, 13-15
- longitudinal course modifiers and, 82
- reliability and validity of assessment and, 83
- pharmacotherapy for, 122-124
- symptomatology of, 12-13
- treatment studies of, 122-124
- Droperidol, in delirium, 441-442
- DRS (Delirium Rating Scale), 434-435
- Drug interactions, after cardiac surgery, 623-624
- in medically ill, depressed patient, 331
- with psychostimulants, 537-538
- Duration. See *Course*.
- Dysfunctional attitudes scale (DAS), 289
- Dysthymic disorder, 41-53, 133-149
- and depressive personality, dimensional models of affective structure and, 113-118
- empirical relationship between, 111-113
- pharmacotherapy for, 124-127
- in double depression, 122-124
- chronic depression as, 133-134
- criteria for, DSM-III, 1-2, 41-42, 79, 111-112
- DSM-III-R, 2, 7, 12, 41-43, 111-112
- DSM-IV Alternative Criteria B for Dysthymic Disorder, 8-9, 42-43, 48, 112-113
- DSM-IV Field Trial, 7-8, 12-13, 111-112
- historical, 12-13
- definition of, 41, 122
- diagnosis of, DSM-IV Field Trial reliability study of, 81
- symptom criteria effect on, 51-52
- diagnostic specificity of, course patterns in, 57
- in DSM-II, 56
- in DSM-III, 56
- in DSM-III-R, 58-59
- treatment outcomes in, 57
- differential diagnosis of, 60-62
- need for academic-clinical synthesis in, 62-63
- major depressive disorder versus, 35-36
- nosology of, 30-31
- pharmacotherapy for, 124-127
- response rates and, 127
- psychotherapy for, 133-149
- brief, 143-144
- follow-up assessment of, 145-146
- in maintenance treatment, 144-145
- outcome studies of, 135-143
- clinical recommendations, 143-146
- discussion of, 142-143
- for combined therapies, 142, 144
- methodologic issues in, 135-136
- serial treatment data in, 141-142
- rationale for, 134
- versus pharmacotherapy for, 134-135
- with interpersonal focus, 144
- with pharmacotherapy, 145
- rates of specific symptoms in, 43-48
- research criteria for, 31
- subaffective type, 106-107
- subtypes and specifiers of, 36-37
- symptom lists for, validity of, 45-47
- symptoms in, criteria for, 41-43, 48
- effect on diagnosis, 51-52
- rates of specific, 43-48
- treatment of, efficacy of, 61-62
- versus major depression, DSM-III and, 109-110
- versus major depressive disorder, 11-12, 30-31
- symptom differences in, 48-51
- Eating Disorder Examination, in binge-eating disorder, 765
- Eating disorders. See also *Anorexia nervosa*; *Bulimia Nervosa*.
- assessment of, anthropometric measurements in, 647
- eating behavior in, 641
- exercise history in, 644
- for binge-eating and purge behavior, 641, 643-644
- nonbulimic causes of, 646-647
- for body image disturbance
- menstrual history in, 644
- questionnaires and interview in, 645-646
- weight history in, 640-642
- atypical, 650
- case formulation for, 650
- comorbid disorders in, medical, 647
- psychiatric, 647
- Type I diabetes mellitus, 676
- comorbidity and outcome in, 843-859
- differential diagnosis of, 659

Eating disorders (*Continued*)

- electrolytes in, 665-666
- endocrinologic aspects of, 670-672
  - laboratory studies for, 672-673
- epidemiology of, **681-700**
  - binge-eating disorder and, 697
  - case detection in, 681, 684
  - case register studies in, 682-688
  - dieting behavior and, 693-695
  - in special populations, 695-696
  - longitudinal studies in, 689, 692-693
  - two-stage studies in, 688-690
  - two-stage studies of, population studies versus, 689-690
- gastrointestinal signs and symptoms in, 666-667
  - treatment of, 668-670
- guide to medical evaluation and complications of, **657-679**
- hematology in, 663-664
- historical perspective on, 657-658
- in athletes, 648-649
- amenorrhea and, 648-649
  - screening for, 649
- in female childhood sexual abuse victims, 773-774
- in women, childhood trauma and complex posttraumatic sequelae in, **773-791**
- infertility and, 650
- initial assessment and early treatment of, **639-655**
  - laboratory evaluation in, 663
  - laboratory evaluation of, endocrinologic, 672-673
  - medical history in, 658-659
  - nutritional management of, **701-713**
  - pharmacotherapy for, **739-754**
  - physical examination in, 660-663
    - cardiovascular, 662
    - gastrointestinal, 663
    - head, eyes, ears, nose, throat findings in, 660-661
    - pulmonary, 662
    - vital signs in, 660
  - psychobiologic influences in, 739-741
  - psychosomatic model of, 639-640
  - subsyndromal, 650
  - treatment of, choice of site and approach in, 651
    - commitment to, 651
    - early options, 651
    - integration of twelve-step and traditional psychotherapies in, **829-840**
  - weight loss in, nonanorexic medical causes of, 646
- ECA (Epidemiologic Catchment Area Program), population-based study of major depression, 91-92
- Elderly, delirium in, 430-431
- depression in, treatment-resistant, **269-286**
- dysthymic disorder in, symptomatology of, 45
- frail, 279-280
- Electroconvulsive therapy (ECT), for anorexia nervosa, 749-750
  - in cardiovascular disease with depression, 335
  - in treatment-resistant depression, 397-398
    - in bipolar disorder, 221-222
    - in elderly patient, 279
    - in gastrointestinal disorders, 338
    - in renal disease, 335
    - psychotic-type, 238, 240
    - with personality disorder, 297
- Electrolytes, abnormalities of, in eating disorders, 665-666
- Energy requirements, in anorexia nervosa, 702-703
- Epidemiologic Catchment Area (ECA) Program, population-based study of major depression, 91-92
- Epilepsy, psychostimulants in, 534
- Ethical issues, in managed care, 458-462
  - confidentiality, 460
  - physician-patient relationship, 460-461
  - society and, 458, 460
- Ethical obligations, in psychiatric care, 458
- Exercise, amenorrhea and, 648
  - response to, chronic fatigue syndrome and, 556
- Exercise therapy, in chronic fatigue syndrome, 566
- Extrapyramidal side effects, of selective serotonin reuptake inhibitors, 505
- Face validation, of psychiatric diagnostic criteria, 74
- Family, and treatment response, in major depressive disorder in children, 257-259
  - of seriously ill child, psychiatric problems of, 483-484, 486
  - treatment-resistant depression and, in children and adolescents, 257-259
  - mood hygiene and, 227
- Family interventions, for abused women, with posttraumatic eating disorders, 784
- Family therapy. See also *Family/marital therapy*.
  - in chronic mood disorders, 23
- Family/marital therapy, education in patient's disorder and, 164-165
  - problem-centered, 163-164
  - response to, 162-163

- treatment phase of, 164  
types of, 163  
with pharmacotherapy, for chronic depression, 154, 157
- Fatness, attitude toward, 693-695
- Fears, in anorexia nervosa, 717-718
- Fibromyalgia, antidepressants in, 353-355
- Five-factor model of affective disorders, 116-118
- Fluid retention, in bulimia nervosa, 708-709
- Fluoxetine, drug interactions with, 502  
hematologic effects of, and drug interactions, 504  
in anorexia nervosa, 748  
in binge-eating disorder, 767  
in bulimia, 651  
in bulimia nervosa, 741-742  
in dysthymia, 20  
versus placebo, 125-126  
in geriatric patients, 276  
in hepatic and renal disease, 505  
in premenstrual dysphoric disorder, 331-332, 364  
side effects of, 504  
with cognitive-behavioral therapy, for bulimia nervosa, 757
- Fluoxetine plus desipramine, in treatment-resistant depression, 206-207
- Fluvoxamine, drug interactions with, 502, 505-506  
hematologic effects of, and drug interactions, 504
- Folate deficiency, in anorexia nervosa, 664
- Food phobia, in anorexia nervosa, 721, 725  
treatment of, 725-731
- GABA-ergic system, in delirium, 438
- Gastric bloating, during refeeding, 668  
prokinetic agents for, 669
- Gastrointestinal disorders, depression in, antidepressants for, 338
- Gastrointestinal tract, adverse effects on, of psychostimulant drugs, 539-540  
complications in, causes of, 666-667  
in anorexia nervosa, 703  
signs and symptoms of, 666-667, 703  
treatment of, 668-670
- Gender, as organizer of behavior, eating disorders and, feminist and psychoanalytic perspectives on, 815-816
- Glutamate, delirium and, 439
- Group therapy, for abused women, with posttraumatic eating disorders, 783-784  
for posttraumatic sequelae of child abuse, 783-784
- Hallucinations, in delirium, 433-434
- Haloperidol, in delirium, 440  
combined with lorazepam, 440-441  
pediatric, 441  
postcardiac surgery, 623
- Head, eyes, ears, nose, and throat examination, in eating disorders, 660-661
- Head injury, psychostimulants in, 533-534
- Heart transplantation, psychiatric problems associated with, 624
- Hepatic disease, depression in, antidepressants for, 335-336
- Heterocyclic agents, high-dose therapy with, 388
- HIV, psychostimulants in, 336
- HIV-positive and AIDS patients, psychostimulants in, 530-532
- Homework assignments, in individual psychotherapy, 162
- Hospitalization, for anorexia nervosa, 651
- Hostility, as coronary artery disease risk, 614
- Human immunodeficiency virus-positive and acquired immunodeficiency disease syndrome patients. *See HIV-positive and AIDS patients.*
- Hypermetabolic thyroid treatment, in treatment-resistant depression, bipolar-type, 222
- Hyperthyroidism, depression in, 332
- Hypoglycemia, in anorexia nervosa, 672
- Hypotension, in anorexia nervosa, 660
- Hypothalamus, abnormal functioning of, in anorexia nervosa, 671
- Hypothermia, in anorexia nervosa, 660
- Hypothyroidism, depression in, 331-332
- Hysteroid dysphoria, 106-109
- Imaging studies, in affective disorders, 261-263, 262
- Imipramine, in binge-eating disorder, 767  
in chronic depression, 130  
in double depression, versus phenelzine in, 124  
versus placebo in, 122-123  
versus sertraline in, 123-124  
in dysthymia, versus ritanserin versus placebo in, 125-126  
long-term therapy with, response to, 128  
with cognitive-behavioral therapy, for bulimia nervosa, 756
- Immune dysfunction, chronic fatigue syndrome and, 558
- Impulse-control disorders, bulimia nervosa and, 855  
in bulimia nervosa, 855  
in women, following child abuse, 777

- Impulse-control disorders (*Continued*)  
 posttraumatic, in women with eating disorders, 777
- Infertility, eating disorder screening and, 650
- Information variance, unreliability and, 77
- Inositol, in treatment-resistant depression, 393
- Interpersonal deficits, in anorexia nervosa, 725  
 treatment of, 731-732
- Interpersonal psychotherapy (IPT), description of, 139-140  
 in chronic mood disorders, 21-22  
 in dysthymic disorder, 139-141, 144  
 pilot data from, 140-141
- Introversion, depressive disorders and, 289
- Iowa 500 study, of chronicity in affective disorders, 89-90
- Ipecac use, by bulimia nervosa patients, 706-707
- IPT. See *Interpersonal psychotherapy (IPT)*.
- Iron-deficiency anemia, in anorexia nervosa, 664
- Irritable bowel syndrome, antidepressants in, 357-359
- Ketoconazole, in treatment-resistant depression, 394-395  
 psychotic-type, 245-246
- Kleptomania, in eating-disorders, 855
- Knowledge, subjective, eating disorders and, 819-820
- Kraepelin, 88, 104
- Lamotrigine, in treatment-resistant depression, 393
- Laureate Program, leaderless organization and, 839  
 philosophy of, 832-834  
 empowerment in, 834  
 mature interdependency in, 833  
 patient in, 834  
 readiness factor in, 833-834  
 tolerance in, 833  
 uniqueness in, 833
- 12-step philosophy in, advantages of, 837-838  
 disadvantages of, 838-839  
 structure of, 834-835  
 day program in, 835  
 individual psychotherapy in, 836  
 12-step component of, 835-836  
 thirteenth step problem in, 839
- Laxative abuse, gastrointestinal sequelae of, 667-668  
 treatment of, 669-670
- Left ventricular assist devices, psychiatric problems associated with, 625-626
- Legal liability, in managed care, 462
- Leukopenia, in anorexia nervosa, 663
- Levels of care, in managed care, 797-798
- Life stress, and depression with personality disorder, 290-291
- Lifetime course profile, in differential diagnosis of double depression, 67-68
- Light therapy. See *Phototherapy*.
- Lithium carbonate, cardiac effects of, 622  
 in anorexia nervosa, 749  
 in augmentation therapy, with antidepressants, 206  
 with monoamine oxidase inhibitors, 378-379  
 with selective serotonin reuptake inhibitors, 382  
 with tricyclic antidepressants, 375  
 in bipolar disorder, 220, 223-224, 229, 232  
 in children aged 6-12, 255-256  
 in geriatric patients, 278
- Liver function, in eating disorders, 666
- Longitudinal course modifiers, for mood disorders, DSM-IV Field Trial  
 reliability study of, 81-82
- L-Tryptophan, for bulimia nervosa, 743  
 in monoamine oxidase inhibitor augmentation, 380
- Magnesium, deficiency of, in eating disorders, 665
- Magnetic resonance imaging (MRI), in affective disorders, 261-263
- Maintenance therapy, in chronic depression, 128-129  
 in chronic mood disorders, 85-87  
 in dysthymic disorder, 144-145  
 in major depression, 160-161
- Major depression, 85-102. See also *Major depressive disorder (MDD)*.  
 chronic, definition of, 122  
 clinical studies of, 88-90  
 course of, population-based studies of, 90-92  
 diagnosis of, DSM-IV Field Trial reliability study of, 81  
 diagnostic specificity of, DSM-III-R, 57-58  
 maintenance therapy for, 160-161  
 manic-depression, in Kraepelin, 88  
 recovery, chronicity, psychopathology in, 16-17, 85-102  
 clinical, 88-90  
 Collaborative Depression Study and, 92-100. See also *Collaborative Depression Study (CDS)*.

- definition of terms in, 87
  - functional outcome of, 91-92
  - historical review of, 88-91
  - long-term course of, 85-87
  - measures of chronicity and, 87-88
  - naturalistic study of, 86
  - population-based study of, 90-91
  - selection bias in, 86-87
  - treatment of, 99
  - Major depressive disorder (MDD), 41-53.
    - See also *Major depression*.
    - after myocardial infarction, mortality and, 617
    - alcoholism correlation with, 257-258
    - case examples of, 37-38
    - dysthymic disorder versus, symptoms and, 48-51
    - in children, treatment response in, 257-259
    - in chronic fatigue syndrome, 553
    - in chronic pain patient, 592
    - in Collaborative Depression Study, 94
    - in primary outpatient care, impact of, 472
    - longitudinal course modifiers in,
      - DSM-IV Mood Disorders Field Trial, 5-6
    - nosology of, 30-31
    - subtypes and specifiers of, 36
    - versus dysthymic disorder, 35-36
    - symptomatology and, 12-13
  - Major depressive episode, criteria for, 79
  - Managed care, aim of, 798
    - ethical issues in, acute psychiatric illness and, diagnosis and treatment of, 458-459
    - for consultation-liaison psychiatry, 461-462
    - least cost versus best treatment, 460
    - patient confidentiality versus review organizations, 460
    - patient loss of choice, 461
    - physician as gatekeeper versus patient advocate, 460-461
    - reparative tasks postdischarge, 458-459
    - social control, 458
    - substance abuse treatment, 458
  - goals of, 452-454
  - in eating-disorder treatment. See also *Toronto Day Hospital Group Treatment Program*.
  - day treatment model for, 803-809
  - in treatment of eating-disorders, attitudes of clinician and, 799
  - authorization for care and, 798-799
  - centers of excellence, 799-800
  - continuum of care and, 799-800
  - contracting, 800
  - outpatient, 799
  - recommendations for future, 799-800
  - strategies for negotiating with, 800-802
  - legal issues, 462
  - mechanisms in, benefit redesign and restructuring, 455
  - capitation, 455
  - carve-outs and consultation-liaison psychiatry, 458-459
  - medical necessity for treatment, 455
  - prevention, 455
  - objectives of, 454-455
  - organizational models of, 453-454
  - recommendations for providers and facilities, 798-799
  - reductions in, cost, 455-456
    - of need for services, 455
    - of treatment variation, 455
  - price, 455
  - terminology in, 797-798
  - treatment of eating-disorder patient and, 793-810
    - effect of limitations on outcomes, 796-797
  - practice guidelines versus treatment limitations, 793-795
- Mania, treatment-emergent, 219-221, 223-224
- Manic episode, in DSM-III, 79
- MDD. See *Major depressive disorder (MDD)*.
- Meaning, alterations in systems of, in women with eating disorders, 781-782
- Medical inpatient sector, psychiatric disorders in, impact of, 468-469
  - intervention in, 470-471
  - recognition of, 470
- Medical necessity, in managed care, 797
- Medical Outcomes Study (MOS) (Rand), in DSM-IV Mood Disorders Field Trial, 4
  - of major depressive disorder and dysthymia, 91-92
- Medical outpatient sector, psychiatric disorders in, identification and course of, 473-474
  - impact of, 471-473
  - intervention studies of, 474-476
- Medically ill patient, treatment-resistant
  - depression in, 329-350
  - drug interactions in, 331
  - in diabetes mellitus, 332-333
  - in gastrointestinal disorders, 338-339
  - in hepatic disease, 335-336
  - in HIV, 336
  - in malignancy, 337-338
  - in neurologic disease, 337
  - in renal disease, 335
  - in respiratory insufficiency, 338
  - in thyroid disease, 331-332
  - in transplantation patients, 336-337
  - interrelationship in, 329-330

- Medically ill patient (*Continued*)  
 misdiagnoses in, 330-331  
 treatment algorithms in, 341-342  
 treatment response in, 185-186
- Medically unexplained illness, medical approach to, 551  
 problem of, 550-551  
 psychiatric approach to, 551
- Medication/psychotherapy combination  
 treatment of chronic mood disorders, 151-171. See also *Pharmacotherapy*.
- Medications, in the treatment of eating disorders, 739-754
- Melancholia, in elderly patients, 274
- Mental status, medication toxicity and, 618
- Metabolic acidosis, from vomiting, in eating disorders, 666
- Methylphenidate (MPD), chemistry and pharmacology of, 519-520  
 dosing of, 536-537  
 following head injury, 533-534  
 in cancer patients, 526-527  
 in elderly, in rehabilitation hospital, 523  
 in subacute care facility, 521  
 in HIV-positive and AIDS patients, 530-532  
 narcotic analgesia synergy with, 535  
 poststroke, 528-529
- Metoclopramide, in anorexia nervosa, 749
- Mexiletine, in chronic pain, 597-598
- Mianserin, response to, in double-blind studies, 189, 191
- Micronutrients, abnormalities in, in bulimia nervosa patients, 707
- Migraine, psychotropic prophylaxis of, 356-357  
 treatment-resistant depression and, 355-357
- Minor depressive disorder, description of, 9-10
- Mitral valve prolapse, in anorexia nervosa, 662
- Moclobemide, in atypical depression, 339-340  
 in dysthymia, versus imipramine versus placebo for, 125-126  
 with selective serotonin reuptake inhibitors, 392
- Monitoring, of food intake and context, in anorexia nervosa treatment, 720-722, 735-736
- Monoamine oxidase inhibitors (MAOIs), adjunctive, in unipolar and chronic depression, 206-207  
 high-dose therapy with, 389  
 in atypical facial pain, 361  
 in gastrointestinal disorders with depression, 338-339  
 in geriatric patients, 275
- in irritable bowel syndrome, 359  
 in treatment-resistant depression, 205  
 augmentation of, cautions with, 380-381  
 with dextroamphetamine, 397  
 with lithium carbonate, 378-379  
 with L-tryptophan, 380  
 with tricyclic antidepressants, 379-380  
 clinical application of, 278  
 high-dose, 380  
 underusage of, 377-378  
 response to, in double-blind studies, 188, 190, 192
- Mood, congruence/incongruence of psychosis and, in treatment-resistance, 246-247  
 cycling of, in bipolar disorder, 217-218, 223, 231  
 agents promoting, 226-227
- Mood charts, in bipolar disorder, 226, 228
- Mood disorders, 1-171  
 chronic, and depressive personality, 17-19, 24, 103-120  
 combination pharmacotherapy for, 22-24, 151-171  
 nosology of, 11-12, 29-39  
 psychosocial treatment of, 21-22  
 differential diagnosis of chronic depressive disorder, 13-15, 55-71  
 issue overview, 10-28  
 medical condition-related, 32  
 pharmacotherapy in treatment of chronic depressive disorders, 19-20, 121-132  
 psychotherapy of dysthymic disorder, 24-25, 133-149  
 recovery, chronicity, levels of pathology in major depression, 16-17, 85-102  
 reliability of diagnosis of, 15-16, 73-84  
 substance-induced, 33  
 symptomatology in dysthymic and major depressive disorder, 12-13, 41-53
- Mood stabilizers, 223-224
- Moral behavior, eating disorders and, feminist and psychoanalytical perspectives on, 819-820
- Morality, in anorexia nervosa, 844-845
- MOS. See *Medical Outcomes Study (MOS) (Rand)*.
- Motivation, in anorexia treatment, 717-719
- MPD. See *Methylphenidate (MPD)*.
- Multidisciplinary pain center, history of, 602-603  
 in chronic pain treatment, effectiveness of, 603-604  
 methodology of, 602-603
- Muscle function, chronic fatigue syndrome and, 556

- NA/N (negative affectivity/neuroticism), 114-115
- Narcotic analgesia, synergistic with amphetamine, 534-535
- Nefazodone, cardiac effects of, 508, 622
- drug interactions with, 508-509
- gastrointestinal effects of, 508
- in cardiovascular disease with depression, 334
- in medically ill patient, 507-508
- in psychotic depression, 245
- response to, in double-blind studies, 191, 193
- Negative affectivity/neuroticism (NA/N), 114-115
- NEO Personality Inventory Revised (NEO-PI-R), 116-118
- Neurasthenia, chronic fatigue syndrome and, 550, 554
- Neuroendocrine abnormalities, chronic fatigue syndrome and, 558-559
- Neuroendocrine modulators, in treatment-resistant depression, 394-395
- Neuroleptics, in anorexia nervosa, 748-749
- in bipolar disorder, 227
- in psychotic depression, dosage adequacy of, 238-239, 247
- Neurologic disorders, psychotic depression in, clozapine for, 241
- Neuroses, chronic depression and, 56
- depressive, 109
- Neuroticism, depressive disorders and, 289
- Neurotransmission, in delirium, 437-438
- Nicotine, refractory depression and, 316-317
- Nitanserin, in double depression, versus placebo for, 122-123
- Noncompliance, after heart transplantation, 624
- Nonsteroidal anti-inflammatory drugs (NSAIDs), psychiatric side effects of, 579-580
- Norfluoxetine, in hepatic and renal disease, 505
- Normality, versus chronic depression, 35
- Nosology of chronic mood disorders, 29-39
- Nutritional management of eating disorders, 701-713
- Nutritional rehabilitation of, gastrointestinal complications of, 668
- Obsessive-compulsive disorder, anorexia nervosa in, 848
- bulimia nervosa and, 853-854
- Opiate addiction, treatment-resistant depression in, 319
- Opioids, gastrointestinal side effects of, 595
- guidelines for use, 596
- in chronic pain, 595-596
- safety and effectiveness of, 595
- Osteopenia, in anorexia nervosa, 705
- in eating disorders, 673-674
- in women with eating disorders, treatment of, 674
- Outcome studies, of anorexia nervosa, 844-846
- of bulimia nervosa, 849-852
- Ovary, in anorexia nervosa, 672
- Overeaters Anonymous, abstinence in, 831, 837
- PA/E (positive affectivity/estraversion), 114-115
- Pain, in children, cancer protocols and, 489
- in terminally ill patient, assisted suicide request and, 424-425
- perception and tolerance of, with substance abuse, 594
- Pain Beliefs and Perceptions Inventory, 600
- Pain disorder, *Diagnostic and Statistical Manual* classifications of, 590-591
- Pain management, advances in, 589-611.
- See also *Chronic pain*.
- consultation-liaison psychiatrist in, 589-590
- psychostimulants in, 534-535
- Parkinson's disease, depression in, treatment of, 337
- Paroxetine, drug interactions with, 503
- in geriatric patients, 275-276
- pharmacokinetics of, 500
- side effects of, 504
- PCSTF. See *Problem-centered Systems Therapy of the Family (PCSTF)*.
- PD. See *Psychotic depression (PD)*.
- Pemoline, chemistry and pharmacology of, 519-520
- in combination therapy, with monoamine oxidase inhibitors, 340
- in medically ill, depressed patients, 338, 340
- Perception, of chronic fatigue syndrome patient, 560
- Personality, in chronic fatigue syndrome, 561
- in coronary artery disease, 614
- in rheumatoid arthritis, 577-578
- Personality disorders, 34. See also *Chronic depression, and depressive personality*.
- anorexia nervosa and, 848-849
- attitudinal style and, 289
- bulimia nervosa and, 854
- bulimia nervosa in, 854
- chronic depression and, 56



Personality disorders (*Continued*)

- classification of, 288-289
- depressive versus chronic depression, 17-18, 35
- dysfunctional attitudes and, 289
- management of, in twelve-step programs, 839
- posttraumatic, in women with eating disorders, 779-781
- treatment resistant depression in, 287-309
  - antidepressant response in, 292-294
  - life stress and, 290-291
  - research in, 291-292
  - treatment plan for, 294-305
    - assessment feedback to patient, 295-296
    - coordination in, 303-304
    - ECT in, 297
    - initial interview in, 295
    - pharmacotherapy in, 296-297
    - psychotherapy in, 297-305
    - treatment response in, 185
  - treatment-resistant depression in, 287-309
- Personality structure, dimensional models of positive and negative affectivity and, 113-115
- Personality traits, treatment-resistant depression and, 288-289
- PET (positron emission tomography), in affective disorders, 261
- Pharmacotherapy, for chronic mood disorders, 22-24, 151-171
  - efficacy of, 155-156
  - issues with, pragmatic, 167-169
    - strategies, 165-167
    - treatment types, 157-165
  - potential effects of, 153
  - rationale for, 152-154
    - biosocial model of illness, 152
    - empirical, 153-154
    - in chronic depression, 155
    - positive and negative effects of, 153
    - theoretical, 152
  - for dysthymic disorder, recommendation for, 145
  - negative and positive possible effects of, 153
- Pharmacotherapy, for chronic depression, response to, 127-129
  - social functioning and, 127
  - for chronic depressive disorders, historical perspective on, 19-20
  - for chronic mood disorders, agents used in, 122-127, 158-159
    - dosage and duration and, 160
    - maintenance therapy and, 160-161
    - polypharmacy versus monotherapy, 159-160
  - response to, 127-129

- symptom-side effect profile matching and, 159
- therapeutic drug monitoring and, 160
- treatment-resistant episodes in, 160
- for double depression, 122-124
- for dysthymic disorder, agents in, 124-127
  - efficacy of, 61-62
- Phenelzine, in chronic depression, long-term therapy with, 128
- Phenytoin, in bulimia nervosa, 743
- Phobic disorders. *See also Food phobia*.
  - anorexia nervosa in, 848
- Phosphate, deficiency of, in anorexia nervosa, 665
  - excess of, with vomiting, 665
- Phototherapy, in treatment-resistant depression, 398
  - in bipolar disorder, 222
- Physician-assisted suicide, arguments against, abuse potential of, 418-419
  - psychiatric intervention as alternative to, 417-418
    - slippery slope danger, 418
  - legalization of, 413-414, 416
    - in Oregon and Australia, 414
  - psychiatric perspective on, 416-420
  - psychiatrist role in, as gatekeeper, 423-424
    - palliative care alternative and, 424-425
    - patient versus psychiatrist value system and, 422
    - screening for treatable psychiatric disorders, 422-423
    - with patient, authenticity of request, 421-422
      - for competency assessment, 420-421
      - with physicians, 414
    - tolerance of, 419-420
- Pimozide, in anorexia nervosa, 748
- Pindolol, in augmentation strategies, 391
- Pituitary function, in anorexia nervosa, 671
- Polypharmacy versus monotherapy, for chronic mood disorders, 159-160
- Positive affectivity/extraversion (PA/E), 114-115
- Positron emission tomography (PET), in affective disorders, 261
- Posttraumatic stress, following serious illness, in pediatric survivors and families, 484
- Potassium, deficiency of, in eating disorders, 665
- Prefrontal cortex, in delirium, 436-437
- Premenstrual dysphoric disorder, treatment-resistant depression and, 361-364
- Prescription drugs, refractory depression and, 316
- Primary care, mental health disorders in, treatment outcome of, 473-474

- psychiatric disorders in, prevalence of, 471-472
- Problem-centered Systems Therapy of the Family (PCSTF), 23, 163-164
- Problems, current, in individual psychotherapy, 162
- Problem-solving techniques, in anorexia nervosa treatment, 727-729, 736-737
- Prokinetic agents, for gastric bloating, 669
- Psychiatric interventions in the medically ill, 467-480. *See also Medical inpatient sector; Medical outpatient sector.*
- criteria for, 468
- length of stay and, 468
- postdischarge course and, 468-469
- Psychiatric sequelae in seriously ill children and their families, 481-493
- causes of, 484-486
- community beliefs and prejudices, 485-486
- developmental disruption, 485
- diagnosis, 484
- economic and social, 486
- overinvolvement of family, 486
- treatment and consequences, 484-485
- interventions in, family groups, 489
- pain and, 489
- psychological preparation, 486-487
- treatment modification, 489
- mediation of, age, 486-487
- culture and ethnicity, 488
- psychological characteristics and, 487-488
- social support, 488
- mediators of, 486-488
- types of, 482-484
- Psychiatry and physician assisted-suicide, 413-427
- Psychoanalysis, in dysthymic disorder, 136
- Psychoanalytic theory, of chronic depression, 105-106
- Psychodynamic psychotherapy, in dysthymic disorder, 136
- Psychoimmunology, in rheumatoid arthritis, 578-579
- Psychosis, affective, 229-230
- depression in, 237-252
- Psychosocial treatment, in chronic mood disorders, 21-22
- Psychostimulants, adjunctive to antidepressants, 205
- in augmentation therapy, for treatment-resistant depression, 396-397
- in cancer patients, 338
- in cardiovascular disease, 334
- in geriatric patients, 277
- in HIV, 336
- in medically ill, depressed patients, 340
- in renal disease, 335
- Psychostimulant(s), amphetamine, 516-518
- chemistry and pharmacology of, 516-520
- contraindications to, 537
- dextroamphetamine, 518-519
- dosing of, 536-537
- drug interactions with, 537-538
- future research directions and, 542
- in cancer, 525-527
- in elderly, in rehabilitation hospital, 523
- in subacute care, 521
- safety of, 524
- in epilepsy, 534
- in head injury, 533-534
- in HIV-positive and AIDS patients, 530-532
- in medically ill patient, 515-547
- efficacy of, 524
- safety of, 524
- studies of, 520-525
- in medical/surgical patients, depressed, 523-524
- in pain management, 534-535
- in rehabilitation patients, 521-523
- inhibition of, 537-538
- methylphenidate, 519-520
- pemoline, 520
- poststroke, 527-529
- side effect sensitivity in, 529
- potentiation of, 537-538
- potentiation of drugs by, 537-538
- side effects of, 528, 529, 539-540
- tolerance, abuse, addiction and, 540-542
- Psychosurgery, in treatment-resistant depression, 399
- Psychotherapy, brief, 143-144, 162
- current problems in, 162
- feminist psychodynamic, for eating disorders, 811-827
- for abused women with posttraumatic eating disorders, 782-783
- in children aged 6-12, 256
- in children and adolescents, 256
- in dysthymic disorder, 133-149
- in medically ill, depressed patients, 338, 340
- in posttraumatic sequelae of child abuse, 782-783
- in treatment-resistant depression, 398
- anger in, 301
- anxiety management in, 300
- behavioral approach in, 301
- borderline personality in, 302
- couples in, 300
- guidelines for, 297-299
- maladaptive beliefs in, 302-303
- psychotherapist-pharmacotherapist team in, 303-304
- social skills in, 301
- stress management in, 300-301
- with personality disorder, 297-304
- individual, for chronic depression, 161-162

- Psychotic depression (PD), treatment  
 response in, 185  
 treatment-resistance in, 237-252  
   antidepressants for, 238-239, 244-245  
   antigluco corticoids for, 245-246  
   antipsychotics in, 238-239, 240-243  
   carbamazepine in, 243  
   combination therapy in, 238  
   definition of, 238  
   diagnosis of, 237  
   ECT in, 238, 240  
   lithium for, 240  
   maintenance therapy for, 247  
   neuroleptics for, 238-239, 247  
   prevalence and rates of, 237, 247  
   psychotic features of, 246-247  
   verapamil for, 245
- Psychotic disorders, 34
- Psychotic states, in systemic lupus  
 erythematosus, 582, 584
- Purging, gastrointestinal consequences of,  
 667-668  
 physiologic consequences of, 643-644
- RDC. See *Research Diagnostic Criteria*  
 (RDC).
- Recovery, from anorexia nervosa, 844-846  
 from bulimia nervosa, 849-851
- Recovery, chronicity, levels of pathology  
 in major depression, 85-102
- Recurrent brief depression, description of,  
 9  
 occurrence of, 10
- Refeeding, gastrointestinal sequelae of, 667
- Reflux, during refeeding, 668
- Relapse, in major depression, clinical  
 variables in, 98-99
- Relationships, of patient with  
 cardiovascular disease, 619  
 physician-patient, in managed care, 460-  
 461
- Reliability, as concept, 73-74  
 comparison with validity, 73-74  
 of diagnosis, in mood disorders, 15-16,  
 73-84  
 of psychiatric diagnosis, 75-76  
   internal consistency of test and, 76  
   joint rating of, 76  
   sources of unreliability and, 77  
   structured interview and, 77-78  
   test-retest assessment for, 76-76  
 studies of, 78-82  
   discussion of, 82-83  
   DSM-II, 78  
   DSM-III, 78-79  
   DSM-III-R, 79-80  
   DSM-IV Mood Disorders Field Trial,  
   80  
     design and procedures of, 80  
     results of, 81-82
- Remittive drugs, in rheumatoid arthritis,  
 psychiatric side effects of, 579-580
- Renal disease, with depression,  
 psychostimulants in, 335
- Reproductive function, in anorexia  
 nervosa, 672
- Research Diagnostic Criteria (RDC),  
 categories of depression, 109  
 in Collaborative Depression Study,  
 92-93
- Reserpine, in treatment-resistant  
 depression, 396
- Respiratory insufficiency, treatment-  
 resistant depression in, 338
- Respiratory system, abnormalities in,  
 chronic fatigue syndrome and, 558
- Rheumatoid arthritis (RA), coping styles  
 and, 578  
 depression and, 579  
 description of, 576-577  
 laboratory findings in, 577  
 medications for, psychiatric side effects  
 of, 579-580  
 multidisciplinary approach to, 580  
 personality profile and, 577-578  
 psychiatric aspects of, 577-580  
 psychoimmunologic aspects of, 578-579  
 treatment of, compliance with, 581  
   depression in, 580  
   pain in, 580  
   psychosocial status and, 580-581
- Rheumatology. See also *Rheumatoid*  
*arthritis (RA)*; *Systemic lupus*  
*erythematosus (SLE)*.  
 psychiatric aspects of, 575-587  
 rheumatologic diseases, autoimmune  
 mechanisms in, 575-576  
 stressful psychosocial events and, 576
- Risperidone, in psychotic depression,  
 treatment-resistant, 242-243
- Rituals, in twelve-step programs, 837
- S-adenosyl-methionine (SAME), in  
 treatment-resistant depression, 393
- SADS (Schedule for Affective Disorders  
 and Schizophrenia) in Collaborative  
 Depression Study, 92-93
- Salicylates, psychiatric side effects of, 579
- SAM (S-adenosyl-methionine), in  
 treatment-resistant depression, 393
- SAS-SR (Social Adjustment Scale-Self-  
 report), 4
- Schedule for Affective Disorders and  
 Schizophrenia (SADS) in Collaborative  
 Depression Study, 92-93
- Schneider, depressive psychopathology in,  
 104-105

- SCID. See *Structured Clinical Interview for DSM-III-R (SCID)*.
- Second messenger system modulators, in treatment-resistant depression, 393
- Seizures, in systemic lupus erythematosus, 583
- Selective serotonin reuptake inhibitors (SSRIs), augmentation of, lithium in, 382
- tricyclic antidepressants in, 376, 381-382
- cardiac effects of, 496
- cardiovascular disease and, 506
- drug interactions with, 501-503, 621
- extrapyramidal side effects of, 505
- for chronic depression, 130
- high-dose therapy with, 389-390
- in chronic depression, 130
- in chronic fatigue syndrome, 566
- in geriatric patients, 275-276
- in heart disease patients, 620-621
- in hepatic and renal disease, 505
- in medically ill patients, 495-496
- in treatment-resistant depression, in cardiovascular disease, 333-335
- in children and adolescents, 254-255
- in gastrointestinal disorders, 338-339
- response to, in double-blind studies, 189-193
- with neuroleptics, for psychotic depression, 244
- Selegeline, in refractory depression, 339
- Self-efficacy, chronic pain and, 600
- Self-monitoring, in individual psychotherapy, 162
- Self-mutilation, posttraumatic, in women with eating disorders, 776-777
- Self-starvation, gastrointestinal sequelae of, 666
- Serotonergic system, chronic fatigue syndrome and, 559
- in delirium, 438-439
- Serotonin system modulators. See also *Selective serotonin reuptake inhibitors (SSRIs)*.
- in augmentation strategies, 390-391
- Sertraline, drug interactions with, 503
- in dysthymia, versus imipramine versus placebo for, 125-126
- Sexuality, conflicted in eating-disorder patient, feminist and psychoanalytical perspectives on, 821-822
- Shame, bodily, in women with eating disorders, 779
- Siblings, of seriously ill children, psychiatric sequelae in, 483-484
- Sleep abnormalities, chronic fatigue syndrome and, 558
- Sleep deprivation, in treatment-resistant depression, 398
- in bipolar disorder, 222
- Social Adjustment Scale-Self-report (SAS-SR), in DSM-IV Mood Disorders Field Trial, 4
- Social impairment, in chronic depression, pharmacotherapy and, 127
- Social support, antidepressant response and, 271
- treatment response in depression and, 186
- Sodium, deficiency of, in eating disorders, 665
- Somatization, as process, 591
- chronic fatigue syndrome and, 554, 559-561
- in chronic pain patient, 591-592
- posttraumatic, in women with eating disorders, 778-779
- primary care outpatient treatment of, 475-476
- Specificity research, in chronic depressions and dysthymic disorder, 56-59
- SSRIs. See *Selective serotonin reuptake inhibitors (SSRIs)*.
- Starvation, cutaneous complications of, 661
- gastrointestinal consequences of, 666-667
- Stigma, chronic fatigue syndrome patient and, 561
- Stress, acute emotional, in sudden cardiac death, 615-616
- psychotherapy and, 300-301
- Structured clinical interview for DSM-III-R (SCID), in DSM-IV Mood Disorders Field Trial, 3-4, 80, 83
- reliability of diagnosis and, 77-78
- Structured retrospective recall, Depression Time Line in, 65-66
- in differential diagnosis of unipolar depressions, 65-67
- Substance abuse, and response to antidepressants, 127
- anorexia nervosa and, 848
- bulimia nervosa and, 854
- chronic pain and, 594
- mood disorder from, 33
- treatment of, as ethical issue, 458
- treatment-resistant depression in, 311-327
- diagnosis of, 317-318
- differential diagnosis of, 318
- evaluation of, 314-317
- interrelationship of, 311-312
- outcome domains in, 312-314
- stress and social network in, 317
- treatment of, 313-314, 318-320
- with depression, treatment response in, 185
- Sudden cardiac death, anxiety as risk factors for, 615-616

- Suicide, as fatal symptom of mental illness, 415-416  
 attempted, in eating disorders, 855  
 in population-based study of affective disorders, 92  
 physician-assisted and psychiatry, 413-427  
 psychiatrist versus nonpsychiatrist perspective on, 414-415  
 terminally-ill patient desire for, 416-417  
 Sulpiride, in anorexia nervosa, 748-749  
 in psychotic depression, treatment-resistant, 243  
 Support network, in twelve-step programs, 838  
 Survey of Pain Attitudes, 600  
 Symptom Checklist-90, in binge-eating disorder, 765  
 Symptomatology in dysthymic and major depressive disorder, 41-53  
 Systemic lupus erythematosus (SLE), 581-585  
   confusion in, 582, 584  
   corticosteroids in, 584-585  
   cyclophosphamide in, 585  
   depression in, 582, 584  
   description of, 581  
   laboratory findings in, 581-582  
   neuropsychiatric problems in, 582-583  
   psychiatric aspects of, 582-584  
   psychotic states in, 582, 584  
   treatment of, 584-585  
 Temperament, depressive, Kraepelin, 104  
 Terminally ill patient, assisted suicide  
   request of, depression and, 422-423  
   for pain, 424-425  
   request for death, authenticity assessment and, 421-422  
   competency and, 420-421  
 Testes, in anorexia nervosa, 672  
 Thalamus, in delirium, 437  
 Therapeutic relationship, in anorexia treatment, 717  
 Thinness, culture of, women with eating disorders and, 781-782  
 Thrombocytopenia, in anorexia nervosa, 664  
 Thyroid function, in eating disorders, 671-672  
 Thyroid hormone augmentation, in geriatric patients, 278-279  
 Tolerance, to antidepressants, 205  
   to psychostimulants, 540-541  
 Toronto Day Hospital Group Treatment Program, for eating disorders,  
   administrative structure of, 804-805  
   admission to, 804  
   advantages of day treatment, 805-806  
   disadvantages of, 806-807  
   efficacy of, 807-809  
   financial structure of, 804-805  
   multidisciplinary approach in, 803-804  
   treatment goals in, 803  
 Tractotomy, subcaudate, in treatment-resistant depression, 222, 399  
 Trait anxiety, psychiatric sequelae of serious childhood illness and, 488  
 Traits, definition of, 116  
   in chronic depression, 116  
   personality, dimensions of, 114  
   negative and positive, 18-19  
 Trazodone, cardiac effects of, 621-622  
   in augmentation strategies, 391  
   in cardiovascular disease with depression, 334  
   in geriatric patients, 276  
   response to, in double-blind studies, 191  
 Treatment-resistant depression  
   assessment of, instruments for, 183  
   prospective versus retrospective, 182-184  
 bipolar, 215-236. *See also Bipolar disorder.*  
   definition of, 215  
   versus unipolar, 215-216, 232-233  
   chronic, 183-184, 201-213  
   chronicity versus, 183-184  
   cognitive impairment and, 273  
   comorbidity and, axis II, 287-309. *See also Personality disorders; Personality traits.*  
   in geriatric patients, 272-274  
   medical, 202-203, 272-273, 329-350  
   psychiatric, 202, 215-236, 237-252, 273-274  
   substance abuse, 311-327  
   definitions of, 179-181, 201  
   in bipolar disorder, 218  
   in children, 253  
   in elderly, 270  
   operational, 180, 194  
   review of, 180  
   diagnosis of, adequacy of, 372  
   drug interactions in, 203  
   environment and, 203  
   epidemiology of, 186-193  
   from inadequate treatment, 272  
   in children and adolescents, 253-267.  
     *See also Child(ren) and adolescents, treatment-resistant depression in.*  
   in disorders on interface of psychiatry and medicine, 351-369  
   atypical facial pain, 359-361  
   chronic fatigue syndrome, 355  
   common etiologic step in, 351-352, 364-365  
   fibromyalgia, 353-355

irritable bowel syndrome, 357-359  
 migraine, 355-357  
 premenstrual dysphoric disorder, 361-364  
 psychotropic medications for, 352-353  
 in elderly patient, **269-286**  
 combination/augmentation strategies in, 278-279  
 ECT for, 279  
 pharmacotherapy for, 274-279  
 sources of, 270-274  
 in medically ill patient, **329-350**  
 in medically ill patients, **329-350**. See also *Medically ill patient*.  
 in substance abuse disorders, **311-327**. See also *Substance abuse*.  
 in unipolar and bipolar depression, **201-213**  
 predictors of, 203-204  
 reevaluation of patient history/presentation, 202-203  
 treatment of, adequacy assessment of, 204  
 ECT in, 207-208  
 strategies for, 205-206  
 incidence of, 371  
 initial management of, 387-388  
 methodologic issues in, 184  
 novel strategies in, **387-405**  
 ECT, 397-398  
 high-dose antidepressant therapy, 388-392  
 light therapy, 398  
 psychopharmacologic agents, 392-397  
 psychosurgery, 399  
 psychotherapy, 398  
 risk:benefit of, 388  
 sleep deprivation, 398  
 nutrition and, 203  
 psychotic, **237-252**. See also *Psychotic depression (PD)*.  
 psychosocial obstacles and, 271  
 recognition failure in, 271  
 treatment algorithms for, **371-386**  
 alternative, 377, 380-381, 382-383  
 for monoamine oxidase inhibitors, 377-381  
 for selective serotonin reuptake inhibitors, 381-382  
 for tricyclic antidepressants, 374-377  
 guidelines for, 383  
 treatment of, dosage and plasma concentrations in, 373-374  
 duration in, 372-373  
 problems in, 371-372  
 response to, partial versus nonresponse, 181-182, 184-186  
 unipolar, **201-213**  
 versus relapse or recurrence, 181

Tricyclic antidepressants (TCAs), and  
 antiarrhythmias postmyocardial  
 infarction, 509  
 high-dose therapy with, 388  
 in atypical facial pain, 361  
 in bipolar disorder, 297  
 in cardiovascular disease, 333  
 in children and adolescents, 254-255  
 in chronic depression, 130  
 in chronic pain, 596-597  
 in diabetes mellitus with depression, 332-333  
 in fibromyalgia, 353-355  
 in gastrointestinal disorders, 338  
 in gastrointestinal disorders with depression, 338  
 in geriatric patients, 274-275  
 in heart disease patients, cardiovascular side effects of, 619-620  
 contraindications to, 620  
 in hepatic disease with depression, 335  
 in irritable bowel syndrome, 359  
 in monoamine oxidase inhibitor augmentation, 379-380  
 in nonresponders, agent switching in, 374  
 algorithm for, 375  
 augmentation of, with lithium carbonate, 375-376  
 with monoamine oxidase inhibitors, 377  
 with selective serotonin reuptake inhibitors, 376-377  
 with triiodothyronine, 376  
 psychostimulants versus, 515-516  
 response to, in double-blind studies, 188, 190, 192-193  
 side effects of, 515-516  
 tamoxifen effect on, 338  
 Triiodothyronine (T<sub>3</sub>), adjunctive, in  
 treatment-resistant depression, 207  
 in antidepressant augmentation, 376  
 Twelve steps and twelve traditions  
 program, 829-831. See also *Laureate Program*.  
 for eating disorders, modifications of, 831-832  
 powerlessness concept in, 832  
 religious versus spiritual orientation in, 831-832  
 interpretation of, 830-831  
 Type A behavior pattern, as coronary artery disease risk, 614

Unipolar depression, **201-213**  
 as clinical challenge, 60  
 diagnosis of, 14  
 differential diagnosis of, 65-67

Unipolar depression (*Continued*)

- treatment-resistant, adequacy of treatment in, 204-206
  - combination therapy in, 206-207
  - nonpharmacologic treatment of, 207-208
  - pharmacotherapy in, 206-207
  - predictors of, 203-204
  - versus bipolar, 215-216, 232-233
- Validation, constant validation method in, 75
- of psychiatric diagnostic criteria, 74-75
  - five-phase approach in, 74-75
  - types of, construct, 75
  - face, 74
- Validity, comparison with reliability, 73-74
- Valproate, in treatment-resistant depression, 393
- Valproic acid, in migraine prophylaxis, 597
- Venlafaxine, in medically ill patient
- pharmacokinetics of, 506-507
- Venlafaxine, high-dose therapy with, 390
- in cardiovascular disease with depression, 334
  - in geriatric patients, 277
- Verapamil, in psychotic depression, 245
- Viral infection, chronic fatigue syndrome and, 557-558

Vitamin status, in anorexia nervosa, 703

- Vomiting, in bulimia nervosa, self-induced, 706-707
- in eating disorders, cutaneous complications of, 661-662
  - gastrointestinal sequelae of, 667-668
  - metabolic acidosis from, 666

Weight, attitude toward, 693-694

- in bulimia nervosa, 706-707
- sports' requirements, eating disorders and, 695

Weight restoration, in anorexia nervosa, 726-731

- cognitive restructuring in, 730-731
  - copied strategies for, 727-728, 730
  - pattern of regular eating for, 726-727
  - problem-solving for, 727-729, 736-737
  - weight range recommendation for, 726
- Women, borderline personality in, 293-294
- major depression in, 94, 98

Zinc deficiency, in anorexia nervosa, 705-706

Zurich study, of chronicity in affective disorders, 89



